

PRESCRIPTION DRUG AFFORDABILITY BOARD MEETING

Monday, March 23, 2026

Virtual Meeting

Minutes

AGENDA ITEM 1

Call the Meeting to Order

Chair Van Mitchell called the meeting to order at 2:03 p.m.

Board Members present: Van Mitchell, Stephen Rockower, M.D., Georges C. Benjamin, MD, MACP, Julia F. Slejko, PhD.

AGENDA ITEM 2

February 23, 2026 Meeting Minutes

Chair Mitchell asked for a motion to approve the February 23, 2026 meeting minutes as submitted. Dr. Rockower made the motion, which Dr. Benjamin seconded. The Board unanimously approved the minutes.

Action: Motion Passed; Minutes APPROVED.

AGENDA ITEM 3

Opportunity for Public Comment

Three entities submitted written comments that have been provided to the Board and posted to the website.

Three people signed up for oral public comment:

1. Derek Flowers, Value of Care Coalition, Agenda items 6 and 7
2. Laura Packard, Voices of Healthcare Action, Agenda items 6 and 7
3. Steve Raabe, Opinion Works, Agenda items 6 and 7

AGENDA ITEM 4

340B Report (Staff Briefing)

Executive Director York provided an overview of the 340B Report as required from HB1056 from the 2024 Legislative Session. The PDAB is required to submit this report to the Legislature by July 1, 2026. PDAB staff sent out and posted a 340B Data Request on March 11, 2026 with responses due on April 10, 2026 to obtain more information for the report. Board members had

the opportunity to ask questions. This presentation is posted on the Board page of the PDAB website.

AGENDA ITEM 5

Updates to Cost Review Study Process and Policy Review Process

Executive Director York provided an update to the Cost Review Study Process and Policy Review Process. Dr. York explained that staff plans to keep the current Cost Review Study Process, but would like to streamline the process to an annual review cycle. The PDAB solicited public feedback on the process through informational hearings on February 10, 2026 and from the PDASC at their February 23, 2026 meeting. Dr. York provided a summary of that feedback and identified certain recommendations for updating the regulations. Chair Mitchell mentioned that a small Board workgroup may be more appropriate to work through the updates to the regulations. The Board had the opportunity to ask questions. This presentation is posted on the Board page of the PDAB website.

AGENDA ITEMS 6 AND 7

Updates for Draft Cost Review Study Report, Policy Review, and UPL (Farxiga and Jardiance)

Dr. Slejko recused herself from the consideration of Farxiga.

Executive Director York explained that he was going to give a combined presentation on Agenda Item 6 and Agenda Item 7. The purpose of the presentation was to review and provide updates concerning: the draft Cost Review Study Reports for Farxiga and Jardiance, Non-UPL policies, calculations and analysis underpinning potential UPL values, and the Draft UPL regulations.

a. Draft Cost Review Study Report (Staff Presentation)

Dr. York advised that the Cost Review Study reports for Farxiga and Jardiance were posted for public comment and those comments are due on March 30, 2026.

b. Non-UPL Policies (Staff Presentation)

Dr. York reviewed the Non-UPL policies for Farxiga and Jardiance.

c. Calculations and Analyses Underpinning Potential UPL Values (Staff Presentation)

Dr. York reviewed the comments received concerning the Farxiga and Jardiance and UPL amount methodology documents that were due on March 4, 2026. Based on the comments received there were no substantive changes to UPL values or calculations.

d. Draft UPL Rules (Staff Presentation)

Dr. York reviewed the following draft regulations: COMAR 14.01.06- Implementation and Monitoring of Upper Payment Limits and COMAR 14.01.07- Upper Payment Limit. Comments on these draft regulations are due on March 30, 2026. The Board had the opportunity to ask questions and discuss. This presentation and relevant materials are posted on the Board page of the PDAB website.

AGENDA ITEM 8

Administrative Update

- Christina Shaklee, Health Policy Analyst provided a short legislative update. This included an update on the PDAB budget hearings and an update on bills that the PDAB has been tracking.

AGENDA ITEM 9

Chair's Update

- Chair Mitchell stated that there will be a special board meeting on April 13, 2026 at 9:00 AM, virtually. There will also be a regularly scheduled Board meeting on May 18, 2026.
- Chair Mitchell stressed the importance of a workgroup for the Cost Review Study Process and Policy Review Process regulation updates.

AGENDA ITEM 10

Closed Session

Chair Mitchell made a motion for the Board to move into closed session, to approve the November 17, 2025 meeting minutes, approve the July 28, 2025 closed session meeting minutes and to Discuss Confidential, Trade Secret and Proprietary Information, under GP § 3-305(b)(13) and HG 21-2c-03(e)(1)(iv); and consult with counsel and receive legal advice concerning confidential information and UPL Procedures under GP § 3-305(b)(7). Ms. Shaklee corrected the record noting that the Board will be approving the November 17, 2025 closed session meeting minutes and the amended July 28, 2025 closed session meeting minutes.

Following the correction, Dr. Benjamin moved to close the session and Dr. Rockower seconded the motion. All Board members voted to close the session; no member opposed the motion. The vote to close the session was taken at 3:16 p.m. The closed session commenced at 3:18 p.m., virtually in a Zoom Breakout room. Dr. Gerard Anderson was absent from today's meeting.

Action: Motion passed; Board adjourned to closed session.

SUMMARY OF CLOSED SESSION

Pursuant to General Provisions, § 3-305(b)(13) and Health-General § 21-2c-03(e)(1)(iv) and § 21-2c-10, Annotated Code of Maryland, on March 23, 2026 at 3:18 p.m., the Board met in closed session to approve certain closed session minutes, discuss proprietary, trade secret and confidential information, consult with counsel and receive legal advice concerning confidential information and UPL procedures under GP § 3-305(b)(7). Van Mitchell, Dr. Rockower, Dr. Benjamin, Dr. Slejko, Assistant Attorney General McDonald (Counsel), Dr. York (Executive Director), Zeid El Kilani (Regulatory Economist), Christina Shaklee (Health Policy Analyst), and Chidera Agwu (Health Policy Analyst) attended the closed session. AAG McDonald provided the Board with legal advice. Dr. Slejko is recused from the consideration of Farxiga. The Board discussed certain proprietary, trade secret and confidential information (in the appendices to the Cost Review Study Reports).

Board Actions

November 17, 2025 Closed Session Meeting Minutes

Dr. Rockower made the motion and Dr. Benjamin seconded the motion to approve the November 17, 2025 closed session meeting minutes. The Board unanimously voted in favor of the motion.

ACTION: Motion passed; Minutes approved.

Amended July 28, 2025 Closed Session Meeting Minutes

Dr. Slejko is recused.

Dr. Rockower made the motion to approve the amended minutes as drafted; Dr. Benjamin seconded the motion. The Board voted (3-0) in favor of the motion to approve the amended minutes; Dr. Slejko was recused.

ACTION: Motion passed; Amended minutes approved.

Adjournment

Dr. Benjamin made a motion to adjourn which Dr. Slejko seconded. The Board voted unanimously to adjourn the closed session and return to open session at 3:39 PM.

AGENDA ITEM 11

Adjournment

Chair Mitchell asked for a motion to adjourn the meeting. Dr. Rockower made the motion to adjourn, which was seconded by Dr. Benjamin. The Board voted unanimously to adjourn.

Adjourned at 3:40 PM